Serum ADMA concentration – an independent factor determining FMD impairment in cardiac syndrome X

References

• Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms. Circulation. 2004;109:568–72.
   PubMed Web of Science ®Google Scholar
• Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659–64.
   PubMed Web of Science ®Google Scholar
• Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilatation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol. 2005;95:1478–80.
   Google Scholar
• Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment. Am J Med. 2006;119:560–6.
   PubMed Web of Science ®Google Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, . Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65.
   PubMed Web of Science ®Google Scholar
• Hinderliter AL, Cuaghey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2003;5:506–13.
   PubMedGoogle Scholar
• Bisoendial RJ, Hovingh GK, de Groot E, Kastelein JJ, Lansberg PJ, Stroes ES. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr Opin Lipidol. 2002;13:595–603.
   PubMed Web of Science ®Google Scholar
• Huang PH, Chen YH, Chen YL, Wu TC, Chen JW, Lin SJ. Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart. 2007;93:1064–70.
   Google Scholar
• Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, . Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–41.
   PubMed Web of Science ®Google Scholar
• Bottcher M, Botker HE, Sonne H, Nielsen TT, Czernin J. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation. 1999;99:1795–801.
   PubMed Web of Science ®Google Scholar
• Bellamy MF, Goodfellow J, Tweddel AC, Dunstan FD, Lewis MJ, Henderson AH. Syndrome X and endothelial dysfunction. Cardiovasc Res. 1998;40:410–7.
   PubMed Web of Science ®Google Scholar
• Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94:130–4.
   PubMed Web of Science ®Google Scholar
• Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974–82.
   PubMed Web of Science ®Google Scholar
• Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, . Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation. 2003;107:429–36.
   PubMed Web of Science ®Google Scholar
• Kolasińska-Kloch W, Leśniak W, Kieć-Wilk B, Malczewska-Malec M. Biochemical parameters of endothelial dysfunction in cardiological syndrome X. Scand J Clin Lab Invest. 2002;62:7–13.
   Web of Science ®Google Scholar
• Kolasińska-Kloch W, Jabrocka A, Kieć-Wilk B, Leśniak W, Kloch M, Dubiel JS, . Relations between endothelial nitric oxide synthase and angiotensin-converting gene polymorphisms and certain biochemical parameters in patients with cardiac syndrome X. Przegl Lek. 2004;61:743–6.
   Google Scholar
• Kolasilska-Kloch W, Leśniak W, Leszczyńska-Gołabek I, Kieć-Wilk B, Kloch M. Exercise tolerance and hyperinsulinemia in cardiological syndrome X. Folia Med Cracov. 2004;45:13–23.
   Google Scholar
• Sen N, Poyraz F, Tavil Y, Yazici HU, Turfan M, Hizal F, . Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. Atherosclerosis. 2009;204:e82–5.
   Google Scholar
• Gornik HL, Creager MA. Arginine and endothelial and vascular health. J Nutr. 2004;134:2880S–7S.
   PubMed Web of Science ®Google Scholar
• Okyay K, Cengel A, Sahinarslan A, Tavil Y, Turkoglu S, Biberoglu G, . Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coron Artery Dis. 2007;18:539–44.
   Google Scholar
• Soysal D, Sumru S, Susam Y. The association of plasma homocysteine, coronary risk factors and serum nitrite in patients with coronary artery disease, vascular syndrome x and healthy subjects. Anadolu Kardiyol Derg. 2003;3:26–34.
   Google Scholar
• Piatti PM, Fragasso G, Monti LD, Caumo A, Van Phan C, Valsecchi G, . Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol. 1999;34:1452–60.
   Google Scholar
• Desideri G, Gaspardone A, Gentile M, Santucci A, Gioffrè PA, Ferri C. Endothelial activation in patients with cardiac syndrome X. Circulation. 2000;102:2359–64.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–316.
   PubMed Web of Science ®Google Scholar
• Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237–54.
   PubMed Web of Science ®Google Scholar
• Tahara A, Yasuda M, Itagane H, Toda I, Teragaki M, Akioka K, . Plasma levels of platelet-derived growth factor in normal subjects and patients with ischemic heart disease. Am Heart J. 1991;122:986–92.
   Google Scholar
• Nilsson J, Volk-Jovinge S, Svensson J, Landou C, De Faire U, Hamsten A. Association between high levels of growth factors in plasma and progression of coronary atherosclerosis. Intern Med. 1992;232:397–404.
   Google Scholar
• Nilsson J, Svensson J, Hamsten A, de Faire U. Increased platelet-derived mitogenic activity in plasma of young patients with coronary atherosclerosis. Atherosclerosis. 1986;61:237–43.
   Google Scholar
• Billett MA, Adbeish IS, Alrokayan SA, Bennett AJ, Marenah CB, White DA. Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients. Arterioscl Thromb Vasc Biol. 1996;16:399–406.
   Google Scholar
• Yeboah J, Sane DC, Crouse JR, Herrington DM, Bowden DW. Low plasma levels of FGF-2 and PDGF-BB are associated with cardiovascular events in type II diabetes mellitus (diabetes heart study). Dis Markers. 2007;23:173–8.
   Google Scholar
• Harrison AA, Dunbar PR, Neale TJ. Immunoassay of platelet-derived growth factor in the blood of patients with diabetes mellitus. Diabetologia. 1994;37:1142–6.
   PubMed Web of Science ®Google Scholar
• Bath PM, Martin JF. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolaemia. J Intern Med. 1991;230:313–7.
   PubMedGoogle Scholar
• Kasprzak JD, Kłosińska M, Drożdż J. Clinical aspects of assessment of endothelial function. Pharmacol Rep. 2006;58:33–40.
   PubMedGoogle Scholar
• Ogawa H, Yasue H, Okumura K, Fujii H, Masuda T, Miyao Y, . Platelet-derived growth factor is released into the coronary circulation after coronary spasm. Coron Artery Dis. 1993;4:437–42.
   Google Scholar